Vanguard Group Inc. increased its holdings in Pfizer Inc. (NYSE:PFE) by 1.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 441,792,969 shares of the biopharmaceutical company’s stock after acquiring an additional 6,620,749 shares during the quarter. Pfizer makes up 0.8% of Vanguard Group Inc.’s portfolio, making the stock its 12th biggest position. Vanguard Group Inc. owned 0.07% of Pfizer worth $19,469,816,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in PFE. Prio Wealth Limited Partnership increased its holdings in Pfizer by 3.2% in the third quarter. Prio Wealth Limited Partnership now owns 1,039,655 shares of the biopharmaceutical company’s stock valued at $45,817,000 after buying an additional 32,071 shares during the last quarter. Sterling Capital Management LLC increased its holdings in Pfizer by 16.6% in the second quarter. Sterling Capital Management LLC now owns 2,478,848 shares of the biopharmaceutical company’s stock valued at $89,933,000 after buying an additional 353,212 shares during the last quarter. Bradley Foster & Sargent Inc. CT increased its holdings in Pfizer by 1.4% in the third quarter. Bradley Foster & Sargent Inc. CT now owns 400,549 shares of the biopharmaceutical company’s stock valued at $17,652,000 after buying an additional 5,393 shares during the last quarter. Round Table Services LLC increased its holdings in Pfizer by 22.7% in the third quarter. Round Table Services LLC now owns 19,327 shares of the biopharmaceutical company’s stock valued at $852,000 after buying an additional 3,580 shares during the last quarter. Finally, Sumitomo Mitsui Financial Group Inc. bought a new stake in Pfizer in the third quarter valued at about $928,000. Institutional investors and hedge funds own 68.61% of the company’s stock.

In related news, insider Mikael Dolsten sold 100,471 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $43.56, for a total value of $4,376,516.76. Following the completion of the transaction, the insider now directly owns 390,097 shares of the company’s stock, valued at approximately $16,992,625.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Douglas M. Lankler sold 38,800 shares of the stock in a transaction that occurred on Wednesday, January 30th. The stock was sold at an average price of $41.19, for a total value of $1,598,172.00. Following the completion of the transaction, the executive vice president now directly owns 83,592 shares of the company’s stock, valued at $3,443,154.48. The disclosure for this sale can be found here. Insiders have sold 308,826 shares of company stock valued at $13,346,258 over the last ninety days. Corporate insiders own 0.06% of the company’s stock.

Several analysts recently weighed in on the company. Cantor Fitzgerald reissued a “buy” rating and issued a $53.00 price objective on shares of Pfizer in a report on Monday, November 19th. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a report on Thursday, January 31st. JPMorgan Chase & Co. lowered Pfizer from an “overweight” rating to a “neutral” rating and set a $46.00 price objective for the company. in a report on Tuesday, December 11th. Zacks Investment Research lowered Pfizer from a “hold” rating to a “sell” rating in a report on Friday, January 25th. Finally, Credit Suisse Group reissued a “neutral” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, January 28th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $44.89.

NYSE:PFE opened at $41.78 on Friday. The company has a market cap of $248.71 billion, a PE ratio of 13.93, a P/E/G ratio of 2.39 and a beta of 0.76. Pfizer Inc. has a 52 week low of $34.32 and a 52 week high of $46.47. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.57 and a quick ratio of 1.33.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.01. The company had revenue of $13.98 billion during the quarter, compared to analyst estimates of $13.92 billion. Pfizer had a return on equity of 26.02% and a net margin of 20.79%. The business’s revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.62 earnings per share. Equities research analysts anticipate that Pfizer Inc. will post 2.86 EPS for the current year.

Pfizer declared that its Board of Directors has initiated a share repurchase program on Friday, December 14th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to repurchase up to 3.8% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

COPYRIGHT VIOLATION NOTICE: “Pfizer Inc. (PFE) Position Lifted by Vanguard Group Inc.” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://theolympiareport.com/2019/03/17/pfizer-inc-pfe-position-lifted-by-vanguard-group-inc.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Read More: What are the reasons investors use put options?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.